BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy. A drug that receives Fast Track designation is eligible for the following:
- More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval
- More frequent communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers
- Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met
- Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, as monotherapy and in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy). Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
About AML
Acute myeloid leukemia (AML) is the most common type of aggressive leukemia in adults, which has the lowest survival rate for all types of leukemia. In 2018, it is estimated there will be nearly 20,000 new cases of AML diagnosed in
About
Contacts
+47 917 86 304
[email protected]
+47 917 86 513
International Media Relations
[email protected]
+44 20 3709 5700
Media Relations in
[email protected]
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/bergenbio-receives-fda-approval-of-fast-track-designation-for-bemcentinib-300942973.html
SOURCE
Missouri Care Signs Agreement with Capital Region Medical Center to Serve Central Missouri’s Medicaid Population
Fallon Health Offers Support in Advanced Illness Care Planning and Decision-Making
Advisor News
- More than half of Gen X investors support parents or children
- Year-end Roth IRA conversions: What you need to know before the deadline
- Debt is limiting American retirement savings
- How starting a conversation with a stranger is like dating
- Why your clients might face higher taxes in retirement
More Advisor NewsAnnuity News
Health/Employee Benefits News
- Making sense of Medicare's hospital rules
- Is long-term care insurance right move?
- Pisgah Legal offering free health insurance help
- Data on Managed Care Reported by Researchers at University of Michigan (Racial/ethnic Disparities In Cost-related Barriers To Care Among Near-poor Beneficiaries In Medicare Advantage Vs Traditional Medicare): Managed Care
- Pay first, deliver later: Some women are being asked to prepay for their baby
More Health/Employee Benefits NewsLife Insurance News